DOCSLIB.ORG

Chronic Hepatitis E Virus Infection by Support*K\YPUN[O Froml03 EASL*PU3 Andvukvu ELPA.9LJLU[S` -\Y[OLYPUMVYTH[PVUYLNHYKPUN03* >Yprofs\YX^Y  -V

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Chronic Hepatitis E Virus Infection by Support*K\YPUN[O Froml03 EASL*PU3 Andvukvu ELPA.9LJLU[S` -\Y[OLYPUMVYTH[PVUYLNHYKPUN03* >Yprofs\YX^Y  -V DECEMBER-,)9 <(20149@ ISSUE0::<, 1(:6/(77(5 DECEMBER-,)9<(9@ 20140::<, ISSUE A review of new data on the treatment of chronic hepatitis C presented at The Liver 7KMeetingH,QWHUQDW 2014LRQDO /LYHU&RQJUHVV WK Alessio Aghemo M.D. PhD Fondazione $SULO IRCCS/RQG Ca’ GrandaRQ Ospedale Maggiore Policlinico I`7YVMLZZVY4HYR\Z7LJR9HKVZH]SQL]PJ di Milano, Milan, Italy and EASL:LJYL[ GoverningHY`.LULYHSVM[ OL,Board\YVWLHU(ZZVJP Member.H[PVU MVY[OL:[\K`VM[OL3P]LY,(:3 Treatment of chronic hepatitis C was in 2330 patients recruited in the US and recommends a 24-week treatment course ;OL0U[LYUH[PVUHS3P]LY*VUNYLZZ03* PU[LYUH[PVUHSH[[LU[PVUMYVT^P[OPUV\Y IL`VUK^OH[PZZ[HUKHYK[YLH[TLU[PU the mainstay,(:3»ZÅ atHNZOPWTLL[PUN the recent AASLDPZ Liver V^Germany.UJVTT\UP[ The combination`HZ^LSSHZ[O of LWsofosbuvirYLZZ >Lof sofosbuvirZ[LYU,\YVW plusLV ledipasvirY[OL<:H in Utreatment-KP[^PSSIL HMeetingWWYVHJOPUNMHZ[HUK^PSSVWLUVU(WYPS in Boston. Although most phase HUplusKT simeprevirLKPH^VYSK^PKL was extremely safe, as PUexperienced[LYLZ[PUN[VZL patientsLOV^[O with L`Lcirrhosis,U]PZHN L 3[O; dataO L.on V]theLYUPU IFN-freeN)VHYKV combinationsM,(:3^HZ of only 2% of patients discontinued due [YLalthoughH[TLU [VMJthis mightOYVUP beJO optimalLWH[P[PZ*P in termsU ]LsofosbuvirY`Z\JJLZZM\ plusSP ledipasvirUW\[[PUN[ andVNL[OL paritaprevirYH ;OtoLO sidePNOSPNO effects,[VM[O an LLespeciallyK\JH[PVUHS remarkable YLofZV\Y efficacyJLSPTP[ at theLKZL[ individual[PUNZ; patientOL> level,/6 OPNOWplus ombitasvirYVÄSLZJPLU[PÄJHUKLK\JH[PVUHS and dasabuvir were WYfeatVNYH if oneT[OP considersZ`LHY^ thatPSSIL[OL, 48% of(:3 patients N\PKLSPULat the populationZ^PSSILKPZJ\ZZLKK\YPUN[OL level this strategy might WYpresentedVNYHT^ inOPJO^PSSH April at EASL’s[[YHJ[HSV International[VM 7VhadZ[ NYHK\H[cirrhosisL* withV\YZL an episode^OPJO^PSSM of previousVJ\Z W\ISPJOLHS[OZLZZPVUHZ^limit access to treatment as drugLSSHZK pricing\YPUN Liver Congress, several compelling VdecompensationU[OL[YLH[TLU[VM] reportedPYHSOLWH[P[PZ in 40% of0U HZmayLWHY beH[ prohibitiveLZ`TWVZP\ for TKmostLKPJ healthcareH[LK[V[ OL 1HZVOHreal-lifeWWHU&RQWHQW data or clinical trials presentedV HKKP[PVU[them. SofosbuvirV[OL7VZ plus[NYHK\H[ simeprevirL*V\YZ was Lalso >/6OLWH[P[PZ*N\PKLSPULsystems. By analyzing PhaseZ II-III studies in Boston are likely to further advance [OLWYVNYHhighly effectiveT^ PSSILZ\WWSLTLUas sustained virological[LK and looking at treatment duration (12 treatment of HCV in the near future. The ^P[responseO1VPU[> (SVR)VYRZOVW ratesZI wereL[^L 89%LU, overall(:3 0HvsTZ 24 \Yweeks)L[OH[[O andLW ribavirinYVNYH TKneedL] inPZL 513KI` HUKHU\TILYVMPU[LYUH[PVUHSTLKPJHS [OL,(:3NV]LYUPUNIVHYK^PSSILHISL :KQO data can be divided into three broad with only a minimal impact of cirrhosis, cirrhotic patients, Bourlière and colleagues HZZVJPH[PVUZPU[OLÄLSKVMSP]LYKPZLHZL [VZH[PZM`[OLULLKZVMWYVMLZZPVUHS +XXY_XMOWOX^categories:$ >RO 3X^ Real-lifeO\XK^SYXKV 6S`O\ data of approved subtype 1a and previous treatment failure were able to suggest that the addition JV]LYPUNH^PKLZLSLJ[PVUVMPTWVY[HU[ OLWH[VSVNPZ[ZHZ^LSSHZWYV]PKLH -YXQ\O]] #regimens,^R + fine-tuningZ\SV 6YXNYX of approved to a protease inhibitor on the efficacy of ribavirin increased the efficacy of the LK\JH[PVUHS[VWPJZPU[OLLHYS`TVYUPUN Z[PT\SH[PUNSLHYUPUNH[TVZWOLYL[OH[^PSS Lc :\YPO]]Yregimens\ 7K\U_] :OM and RCTsU<K ofNY]K experimental`VTO`SM ^VratesYRZOVWZ in subgroup^P[OJ analysis.SPUPJHSZ`TWVZPHHZ THR12-weekL[OLH schedule[[LUKHUJ of LH[[Osofosbuvir/ledipasvirL03*H]LY` =OM\O^K\c 1drugs.OXO\KV / HCV+= Target6 provided the most ^LSSHZ[OLNYHUKYV\UKZ YLtoTHYRHISLL 96% overall,]L makingU[ it as effective as @SOXXK +interesting_]^\SK data in the first group In the fine-tuning group of studies, Marc the 24-week ribavirin-free arm (98% SVR). of studies as it reported safety and ;OBourlièreLZJPLU[PÄ fromJW Marseille,YVNYHTP FranceZZL[[VI stoleLL]L theU :VThis0J pieceVYKPHSS`P of informationU]P[L`V\[ hasVQ VPimportantU\ZPU :KQO efficacy of sofosbuvir and simemprevir TVYshowLL_J whenP[PUN[OPZ` reportingLHY a HsubgroupZPUKPJH[ analysisLK 3VUKVUPU(clinical implicationsWYPSH[[O as Lit highlights [O,(:3 that .OPO\\KV YP ^\OK^WOX^ SX 2-@ ZK^SOX^]$ <S]U] I`HYof phaseLJVY II-IIIKIYL trialsHRPU of NtreatmentH withIZ[YHJ[Z JVUNribavirinYLZ stillZH hasUK0O a placeVWL[OH[T in second-HU` Z\ITP[[LK[V[OL03*(TVUNZ[[OLZL PUNYLKPLU[Z^PSSJVU[YPI\[L[V^OH[^L KXN LOXOPS^] sofosbuvir + ledipasvir. This one pill-a-day generation interferon-free regimens, as it [OLTVZ[Hregimen receivedU[PJPWH[ FDALKVUL approvalZ^PSSIL[OVZL in the [OPUR^PSSILV\YSallows for shorter HYandNLZ cheaper[0U[LYUH treatment[PVUHS Lc :\YPONewsletter]]Y\ +VLO\ Contents^Y +VLO\^S WYlastLZLU month,[PUN[O andLK isH[HVMHS expectedHY NtoLU receive\TIL YVM 3Pschedules]LY*VUNYLZ withoutZ[VK compromisingH[L efficacy. :KNY`K 3^KVc Page 1 - 2 WOHZLEMA approval[YPHSZVMH shortly.SSVYHSKY\N[YLH[TLU[Z The FDA label A review of new data on the treatment of MVYJOYVUPJOLWH[P[PZ*)\[^OPSL[OLZL Continued on page 2 :KQO hepatitis C by Alessio Aghemo, M.D PhD [YPHSZ^PSSTHRLTVZ[VM[OLOLHKSPULZ ++Milan,=6. Italy$ 8Oa N\_Q] PY\ -R\YXSM [OL03*VќLYZT\JOTVYL[OHUQ\Z[[OL [YLH[TLU[VM]PYHSOLWH[P[PZ 7YVMLZZVY4HYR\Z7LJR9HKVZH]SQL]PJ 2OZK^S^S] , Hepatitis B and C Public Policy Association commissioned article is now available Page 2 - 3 :LJYL[HY`.LULYHS,(:3 The Gilead Sciences Research Scholar Lc .\ ASVVOW : ,\Y_aO\ KXN The5VUPU Hepatitis]HZP]LL]H B andS\H[PVUV C PublicMSP]LY Policy Association’s:[LSS]LY Working[YL[LUKL GroupY(I[LPS\UNZSLP report on[LY Program in Liver disease 2015 with :\YPO]]Y\ 2K\\c 6+ 4KX]]OX BarriersKPZLHZL Wto VYcare[HSO and`WLY treatment[LUZPVUHUKHSZV for patients with<UP] chronicLYZP[p[ZRS viralPUPRM hepatitis, Y0UULYL4 withLK GeorgePaPU000 Prof Michael P. Manns -KXKNK KXN ^RO 8O^RO\VKXN] Papatheodoridis[YLH[TLU[VMWYPTHY and`I HeinerPSPHY`J PYYOVZPZ^PSSWedemeyer as 2SPUPZJOprincipalL( investigators, wasI[LPS\UNM\Y.HZ[YVLU[ publishedLYVSVNPL Page 3 asYLWY a LZLUsystematic[V[OLYO reviewPNOSPNO[ articleZVM[O inL0 Liver3* International\UK/LWH[ earlierVSVNPL this year. ‘Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review’ How a reduced price for Sofosbuvir was Q\Z[[VTLU[PVUHML^-YVTHW\ISPJ >pOYPUNLY. Y[LS :KQO Liver International ISSN 1478-3223. The report is freely accessible on obtained for Egypt by Prof Gamal Esmat, WVSPJ`WVPU[VM]PL^[OLOV[[VWPJ^PSS ( >PLU /\KNSMK^SYX YP 2OZK^S^S] - `S\_] 2-@$ http://onlinelibrary.wiley.com/doi/10.1111/liv.12565/pdf. Cairo, Egypt IL[OLSH\UJOVM[OL>/6N\PKLSPULZ :Y]]SLSVS^c Y\ PKX^K]c ,THPS!THYR\ZWLJR'TLK\UP^PLUHJH[ Page 4 - 5 TVheU[O reportL[YLH[T wasLU commissioned[VMJOYVUPJOLW byH[P[ thePZ Hepatitis B and C PPA, with non-financial Lc :\YPO]]Y\ 4Y\NKX 4 0OVN Chronic hepatitis E virus infection by support*K\YPUN[O fromL03 EASL*PU3 andVUKVU ELPA.9LJLU[S` -\Y[OLYPUMVYTH[PVUYLNHYKPUN03* >YProfs\YX^Y -V. KXKNKMallat and S. Pol, Paris, France >/6OHZJVTWPSLKN\PKLSPULZVU[OL JHUILMV\UKH[[OL,(:3^LIZP[L! THUHNLTLU[VMOLWH[P[PZ*^OPJONV ^^^LHZSL\ 1 (QTXLULHVWREnquiries+HSDWLWLV% & to: Hepatitis3XEOLF3ROLF B & C Public Policy\$V AssociationVRFLDWLRQDVEO_ asbl | email:HPDL [email protected]ǸFH#KHSEFSSD RUJ www.hepbcppa.org ZZZKHSEFSSDRUJ DECEMBER 2014 ISSUE Several new compounds were presented genotype 1 patients with advanced companies, which should translate into at the Liver Meeting including the fibrosis or with a previous treatment a rapid decrease in costs of drugs for second-generation NS5A inhibitor failure with pegylated interferon-based healthcare systems. A key factor if broad GS-5816 which managed to achieve regimens. Both interferon-free regimens and equal access to these drugs across high SVR rates in combination with were extremely safe with less than Europe is to be achieved. sofosbuvir. Still the most compelling data 3% of patients discontinuing due to came from the Phase III studies of the side effects and without any significant Alessio Aghemo, M.D. PhD. combination of grazoprevir (protease safety signal in these two large Phase III Division of Gastroenterology and inhibitor) plus elbasvir (NS5A inhibitor) studies. These efficacy and safety rates Hepatology, Fondazione IRCCS Ca’ and the combination of daclatasvir are not surprising nowadays. Given the Granda Ospedale Maggiore Policlinico (NS5A) plus asunaprevir (protesase fact that in the past limited access to di Milano and Università degli Studi di inhibitor) and beclabuvir (NS5b Non- treatment hampered the effectiveness Milano, Italy nucleoside inhibitor). These 2 different of anti-hepatitis C therapy hence, any Email: [email protected] interferon strategies managed to reach new player in the therapeutic field should 90-100% and 93-98% SVR rates, be viewed positively as this will likely respectively in difficult-to-cure HCV lead to competition between pharma The Gilead Sciences Research Scholars Program: An interview with Professor Michael Manns, Chairman of the The Gilead Sciences Research Scholars Committee. Q1. Could you kindly explain the Gilead Sciences The applicant should also be able to obtain/secure a faculty Research Scholars Program for our readership? position within the next 3 years and should devote his academic career to research in liver diseases. The Gilead Sciences Research Scholars Program is a very attractive program for junior researchers to obtain funding to the Q2: As the Chairman of the Committee, what are the value of US$ 130,000, which is paid in two annual installments features you are looking for when evaluating a research of up to US$ 65,000 each. The Gilead Sciences Research project proposal? Scholars Program is active in various fields of medicine including cardiovascular disease, primary pulmonary hypertension, cystic The package of the research proposal consists of the applicant, fibrosis, haematology and oncology as well as liver diseases. the mentor, the institution, and the project. We evaluate The Liver Disease Research Scholars Program has a North the applicant concerning his past and present research American as well as an International Program.
Load more

Recommended publications
  • Treatment Program Policy Analysis 2017
    Public Disclosure Authorized Public Disclosure Authorized Public Disclosure Authorized Public Disclosure Authorized Treatment Program Analysis Treatment Policy PROGRAM Egypt’s Viral Hepatitis Program Treatment Program Policy Analysis 2017 This report is developed as part of the World Bank’s Technical Assistance on Strengthening Egypt’s Response to Viral Hepatitis. Comments and suggestions concerning the report contents are encouraged and could be sent to [email protected] 2 © 2017 International Bank for Reconstruction and Development / The World Bank 1818 H Street NW Washington DC 20433 Telephone: 202 473 1000 Internet: www.worldbank.org This work is a product of the staff of The World Bank with external contributions. The findings, interpretations, and conclusions expressed in this work do not necessarily reflect the views of The World Bank, its Board of Executive Directors, or the governments they represent. The World Bank does not guarantee the accuracy of the data included in this work. The boundaries, colors, denominations, and other information shown on any map in this work do not imply any judgment on the part of The World Bank concerning the legal status of any territory or the endorsement or acceptance of such boundaries. Rights and Permissions The material in this work is subject to copyright. Because The World Bank encourages dissemination of its knowledge, this work may be reproduced, in whole or in part, for noncommercial purposes as long as full attribution to this work is given. Any queries on rights and licenses, including subsidiary rights, should be addressed to the Office of the Publisher, The World Bank, 1818 H Street NW, Washington, DC 20433, USA; fax: 202 522 2422; e-mail: [email protected].
    [Show full text]
  • Elbasvir and Grazoprevir for Chronic Hepatitis C Genotypes 1 and 4
    Expert Review of Clinical Pharmacology ISSN: 1751-2433 (Print) 1751-2441 (Online) Journal homepage: http://www.tandfonline.com/loi/ierj20 Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4 Mohamed El Kassas, Tamer Elbaz, Yasmeen Abd El Latif & Gamal Esmat To cite this article: Mohamed El Kassas, Tamer Elbaz, Yasmeen Abd El Latif & Gamal Esmat (2016): Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4, Expert Review of Clinical Pharmacology, DOI: 10.1080/17512433.2016.1233813 To link to this article: http://dx.doi.org/10.1080/17512433.2016.1233813 Accepted author version posted online: 07 Sep 2016. Published online: 26 Sep 2016. Submit your article to this journal Article views: 19 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ierj20 Download by: [T&F Internal Users], [Priti Nagda] Date: 18 October 2016, At: 05:00 EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016 http://dx.doi.org/10.1080/17512433.2016.1233813 DRUG PROFILE Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4 Mohamed El Kassasa, Tamer Elbazb, Yasmeen Abd El Latifc and Gamal Esmatb aEndemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt; bEndemic Hepatogastroenterology, Faculty of Medicine, Cairo University, Cairo, Egypt; cTropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt ABSTRACT ARTICLE HISTORY Introduction: During the last few years, treatment of hepatitis C virus (HCV) revolutionized with the Received 16 June 2016 appearance of direct antiviral agents especially for patients with HCV genotypes 1 and 4 infections.
    [Show full text]
  • WGO GUIDANCE for PATIENTS with COVID-19 and LIVER DISEASE
    1 WGO GUIDANCE FOR PATIENTS WITH COVID-19 and LIVER DISEASE (By members of the Hepatology Interest Group of WGO) Contributors in alphabetical order: MR Alvares da Silva, KW Burak, T Chen, JPH Drenth, G Esmat, R Gaspar, D LaBrecque, A Lee, G Macedo, B McMahon, Q Ning, N Reau, M Sonderup, DJ van Leeuwen. Edited by S Hamid, D Armstrong and C Yurdaydin Topics: i. Introduction and general approach to the patient with COVID-19 and elevated liver enzymes Ii. Liver co-morbidities and COVID-19 iia. Chronic hepatitis B and C iib. Metabolic dysfunction-associated fatty liver disease (MAFLD) and COVID-19 iic. Autoimmune liver diseases and COVID-19 Iii. Practical aspects of caring for chronic liver disease patients in the COVID-19 era iiia. How to follow chronic liver disease patients during COVID-19 iiib. Performing procedures during COVID-19 Iiic. Therapies under investigation for COVID-19 and potential hepatotoxicity Iv. Management of complications of liver disease: iva. Screening and treatment of hepatocellular carcinoma (HCC) Ivb. Liver transplantation in the COVID-19 era 1 2 I. Introduction and General Approach To The Patient With COVID-19 and Elevated Liver Enzymes Alice Lee (Australia), Qin Ning and Tao Chen (China), Dirk J van Leeuwen (USA) The World Health Organization declared a global pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on March 11, 2020. To date, worldwide there have been approximately 5 million confirmed cases of coronavirus disease 2019 (COVID-19). Worldwide, many of us are overwhelmed by the increased demands that this infection has put on our healthcare systems and our personal work.
    [Show full text]
  • Impact of Different Anti-HCV Regimens on Platelet Count During Treatment in Egyptian Patients Sara Abd El Ghany1, Noha M
    Ghany et al. Egyptian Liver Journal (2020) 10:45 https://doi.org/10.1186/s43066-020-00054-8 Egyptian Liver Journal ORIGINAL RESEARCH ARTICLE Open Access Impact of different anti-HCV regimens on platelet count during treatment in Egyptian patients Sara Abd El Ghany1, Noha M. El Husseiny1,2* , Mohamed Roshdy1, Heba Moustafa1, Mohamed Taha Atallah3, Ahmed Fathy1,2, Heba H. El Demellawy4, Asmaa M. Abdelhameed1,2 and Doaa M. El Demerdash1 Abstract Background: Side effects of antiviral therapies for hepatitis C, especially hematologic abnormalities, may decrease both therapeutic adherence and therapeutic success rate. Adherence to therapy is essential to achieve an early viral response (EVR), and this is vital for attaining a sustained viral response (SVR). Discontinuation of anti-viral therapy is the only way to prevent progressive thrombocytopenia; however, discontinuation of therapy may reduce the rate of viral clearance and SVR. Our aim is to study effects of antiviral therapy for HCV on platelet count. One hundred sixty eight adult patients with chronic hepatitis C were enrolled in this study and subcategorized into 3 groups: group (1) contains 56 patients receiving IFN, ribavirin and sofosbuvir (triple therapy); group (2) contains 55 patients receiving ribavirin and sofosbuvir (SOF/RBV); and group (3) contains 57 patients receiving simeprevir and sofosbuvir (SIM/SOF). HCV RNA by PCR were checked basically for all studied patients. Follow-up platelet count was done weekly during the first month then monthly till end of treatment. Follow-up of platelet count decrement was assessed at the 2nd week, 4th week and end of antiviral therapy for all studied groups.
    [Show full text]
  • Towards HCV Elimination in Egypt by 2020
    Towards HCV Elimination in Egypt by 2020 Prof. Gamal Esmat Prof. Hepatology &Ex. Vice President of Cairo University, Egypt Member of WHO Strategic Committee for Viral Hepatitis www.gamalesmat.com Elimination • Vision “A world where viral hepatitis transmission is stopped and everyone has access to safe, affordable and effective treatment and care” • Elimination as a public health issue of concern - remove sustained transmission, remove hepatitis as a leading cause of mortality: – Elimination and not eradication: long wave of prevalence will remain for decades Global prevalence &genotype distribution Geographic HCV prevalence 1996 Alexandria 5.9% (95% CI: 4.2-7.7) Cairo 8.2% (95% CI: 6.7-9.8) L Lower Egypt I 28.4% B (95% CI: 27.1-29.2) Y A Middle Egypt Red 26.5% Sea (95% CI: 23.7-29.4) Upper Egypt 19.4% (95% CI: 17.2-21.6) EGYPT Frank et al., (2000) SUDAN Trends in Percentage of population age 15-59 testing positive HCV Ab, Egypt 1996-2008-2015 Chart Title 1996 2008 2015 25.8 22.9 20.1 16.6 14.2 11.8 12 10 9 total Women Men Our aim to maintain a disease Control (by reaching international prevalence disease rates with 2% infection rate compared with the current 7% infection rate). To reach for disease Elemination (disease rate <1%) Waked,……,Esmat.et.al .Ar.J.G.2014 Phase 1 Interferon Treatment for some Opening of 23 national treatment centres, 2007-2013 Total number of patients treated with PEG-IFN (2007-2013): 350,000 Annual number of new patients treated: 45,000 Annual budget from the Ministry of Health: 90 million $ Better understanding of therapeutic targets Phase 2 DAA Treatment for All • Increase policymakers’ commitment to supporting the policy change necessary to prevent viral hepatitis transmission.
    [Show full text]
  • New Treatment for HCV G4 Towards an End to HCV Epidemic in Egypt
    New Treatment for HCV G4 Towards an End to HCV Epidemic in Egypt Prof. Gamal Esmat Prof. Hepatology &Vice President of Cairo University, Egypt Member of WHO Strategic Committee for Viral Hepatitis www.gamalesmat.com Hepatitis C Genotypes -In Europe <10% c - in US >15% Middle East : a >80% 4 2 b South-East- Asia 6 5 Southafrica >30% in some (>50%) areas 3 1 c a a - In Europe. 20 % b b - i.v. drugs - India >80% - Thailand >70% Genotype 4 •HCV genotype 4 accounts for approximately 15% of all cases of chronic HCV worldwide. •Genotype 4 predominates throughout the Middle East and parts of Africa, often in association with a high population prevalence as in Egypt •More than 90% of Egyptian HCV isolates belong to genotype 4 •Phylogenetic analysis of the complete genomic sequence of genotype 4 revealed a closer relationship between genotype 4 and genotype 1 than with other genotypes Habib et al, Hepatology 2001; 33: 248-253 Angelico et al, J Hepatol 1997; 26: 236-43 Epidemiology of G4 HCV genotype 4 prevalence % Country 91 % Egypt 76 % Cameroon 71 % Gabon 60 % Nigeria 60 % Saudi Arabia 30 % Lebanon 30 % Syria 14 % Southern Spain 7.4 % Southwestern France 6.2 % Southern India 3.6 % Germany 3.1 % Northern Italy 1.4 % Southern Italy Wantuck et al ., Aliment Pharmacol Ther 2014 Global genotype distribution Egyptian National Control Strategy for Viral Hepatitis 2008-2012 April 2008 Arab Republic of Egypt, Ministry of Health and Population National Committee for the Control of Viral Hepatitis HCV Egypt 2008 Overall Prevalence 14% 50 49,3 45 43,5 40
    [Show full text]
  • Fibroscan, APRI, FIB4, and GUCI
    Arab Journal of Gastroenterology 17 (2016) 78–83 Contents lists available at ScienceDirect Arab Journal of Gastroenterology journal homepage: www.elsevier.com/locate/ajg Original Article FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection ⇑ Ayman Yosry a, Rabab Fouad a, Shereen A. Alem a, , Aisha Elsharkawy a, Mohammad El-Sayed a, Noha Asem b, Ehsan Hassan c, Ahmed Ismail d, Gamal Esmat a a Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt b Public Health Department, Faculty of Medicine, Cairo University, Cairo, Egypt c Pathology Department, National Hepatology and Tropical Medicine Research Institute (NHTMRI), Cairo, Egypt d Hepatology Department, National Hepatology and Tropical Medicine Research Institute (NHTMRI), Cairo, Egypt article info abstract Article history: Background and study aims: Multiple noninvasive methods have been used successfully in the prediction Received 18 November 2015 of fibrosis. However, their role in the prediction of response to hepatitis C virus (HCV) antiviral therapy is Accepted 24 May 2016 debatable. The aim of this study was to validate and compare the diagnostic performance of FibroScan, APRI (aspartate aminotransferase (AST)-to-platelet ratio index), FIB4, and GUCI (Göteborg University Cirrhosis Index) for the prediction of hepatic fibrosis and treatment outcome in HCV-infected patients Keywords: receiving pegylated interferon and ribavirin (PEG-IFN/ribavirin). Chronic hepatitis C virus Patients and methods: This study included 182 Egyptian patients with chronic HCV infection. They were FibroScan classified into two groups based on the stages of fibrosis: mild to significant fibrosis (F1–F2) and Aspartate aminotransferase-to-platelet ratio index advanced fibrosis (F3–F4).
    [Show full text]
  • Progress Report on Access to Hepatitis C Treatment
    PROGRESS REPORT ON ACCESS TO HEPATITIS C TREATMENT FOCUS ON OVERCOMING BARRIERS IN LOW- AND MIDDLE-INCOME COUNTRIES MARCH 2018 A patient holds her hepatitis C medicines at the MSF hepatitis C clinic at Preah Kossamak Hospital in Phnom Penh, Cambodia CREDIT: TODD BROWN PROGRESS REPORT ON ACCESS TO HEPATITIS C TREATMENT FOCUS ON OVERCOMING BARRIERS IN LOW- AND MIDDLE-INCOME COUNTRIES MARCH 2018 WHO/CDS/HIV/18.4 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.
    [Show full text]
  • Ledipasvir/Sofosbuvir with Or Without Ribavirin for 8 Or 12 Weeks For
    Hepatology ORIGINAL ARTICLE Ledipasvir/sofosbuvir with or without ribavirin for Gut: first published as 10.1136/gutjnl-2017-315906 on 17 April 2018. Downloaded from 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt Gamal Shiha,1,2 Gamal Esmat,3 Mohamed Hassany,4 Reham Soliman,2,5 Mohamed Elbasiony,1,2 Rabab Fouad,3 Aisha Elsharkawy,3 Radi Hammad,4 Wael Abdel-Razek,6 Talaat Zakareya,6 Kathryn Kersey,7 Benedetta Massetto,7 Anu Osinusi,7 Sophia Lu,7 Diana M Brainard,7 John G McHutchison,7 Imam Waked,6 Wahid Doss4 ► Additional material is ABSTRact published online only. To view Objective We evaluated the efficacy and safety of Significance of this study please visit the journal online ledipasvir/sofosbuvir alone and with ribavirin for 8 (http:// dx. doi. org/ 10. 1136/ What is already known about this subject? gutjnl- 2017- 315906). and 12 weeks in Egyptian patients with and without In Egypt, which has one of the highest 1 cirrhosis, who were infected with hepatitis C virus ► Internal Medicine Department, prevalences of hepatitis C virus (HCV) infection Mansoura University, Mansoura, (HCV) genotype 4, including those who had failed Egypt previous treatment with sofosbuvir regimens. in the world (6.3%), >90% of patients are 2Egyptian Liver Research Design In this open-label, multicentre, phase III study, infected with HCV genotype 4. Institute and Hospital (ELRIAH), treatment-naive patients were randomised to receive ► At the time of study design, sofosbuvir was the Mansoura, Egypt 8 or 12 weeks of ledipasvir/sofosbuvir±ribavirin.
    [Show full text]
  • Excess Mortality Rate Associated with Hepatitis C Virus Infection: a Community-Based Cohort Study in Rural Egypt
    Research Article Excess mortality rate associated with hepatitis C virus infection: A community-based cohort study in rural Egypt Aya Mostafa1,y, Yusuke Shimakawa2,y, Ahmed Medhat3, Nabiel N. Mikhail4, Cédric B. Chesnais2,5, Naglaa Arafa1, Iman Bakr1, Mostafa El Hoseiny1, Mai El-Daly6,7, Gamal Esmat8, ⇑ Mohamed Abdel-Hamid6,9, Mostafa K. Mohamed1, Arnaud Fontanet2,10, 1Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt; 2Unité d’Épidémiologie des Maladies Émergentes, Institut Pasteur, Paris, France; 3Department of Gastroenterology & Tropical Medicine, Faculty of Medicine, Assiut University, Assiut, Egypt; 4Department of Biostatistics and Cancer Epidemiology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt; 5UMI 233, Institut de Recherche pour le Développement (IRD), Montpellier, France; 6Viral Hepatitis Research Laboratory, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt; 7National Liver Institute, Menoufia University, Menoufia, Egypt; 8Endemic Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt; 9Department of Microbiology and Immunology, Faculty of Medicine, Minia University, Minia, Egypt; 10Département d’Infection et Épidémiologie, Conservatoire National des Arts et Métiers, Paris, France Background & Aims: >80% of people chronically infected with Conclusions: Use of a highly potent new antiviral agent to treat hepatitis C virus (HCV) live in resource-limited countries, yet all villagers with positive HCV RNA may reduce all-cause mortal- the excess mortality associated with HCV infection in these set- ity rate by up to 5% and hepatic mortality by up to 40% in rural tings is poorly documented. Egypt. Methods: Individuals were recruited from three villages in rural Ó 2016 European Association for the Study of the Liver.
    [Show full text]
  • Sofosbuvir Plus Ribavirin for Treating Egyptian Patients with Hepatitis C Genotype 4
    Research Article Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4 ⇑ Wahid Doss1, Gamal Shiha2, , Mohamed Hassany1, Reham Soliman2, Rabab Fouad3, Marwa Khairy3, Waleed Samir2, Radi Hammad1, Kathryn Kersey4, Deyuan Jiang4, Brian Doehle4, Steven J. Knox4, Benedetta Massetto4, John G. McHutchison4, Gamal Esmat3 1National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt; 2Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt; 3University of Cairo, Cairo, Egypt; 4Gilead Sciences, Inc., Foster City, CA, United States Background & Aims: Egypt has the highest prevalence of chronic Introduction hepatitis C virus (HCV) infection in the world, and more than 90% of patients are infected with genotype 4 virus. We evaluated the Egypt has the highest prevalence of hepatitis C virus (HCV) infec- efficacy and safety of the HCV polymerase inhibitor sofosbuvir in tion in the world [1]. The prevalence of HCV viremia was estimated combination with ribavirin in HCV genotype 4 patients in Egypt. to be 7.3% for the year 2013 [2,3] on the basis of data from the 2008 Methods: Treatment-naïve or treatment-experienced patients Egypt Demographic and Health Survey [4]. Egypt also has the with genotype 4 HCV infection (n = 103) were randomly assigned greatest number of patients with genotype 4 HCV, more than to receive either 12 or 24 weeks of sofosbuvir 400 mg and rib- 90% of those infected or approximately six million people [5]. avirin 1000–1200 mg daily. Randomization was stratified by Within the country, the prevalence of HCV varies among age prior treatment experience and by presence or absence of cirrho- groups and is highest in persons who received parenteral sis.
    [Show full text]
  • SVR12 by HCV Genotype
    HCV Treatment in the Era of DAA Prof. Gamal Esmat Prof. Hepatology & Vice President of Cairo University, Egypt Member of WHO Strategic Committee for Viral Hepatitis www.gamalesmat.com Global genotype distribution . Under auspices of Ministry of Health. Implemented in association with DHS Egypt and MACRO international. Funding from USAID and UNICEF. Hepatitis C testing undertaken at the central Laboratory of MOH. Household survey in 28 governorates. ELISA test used to determine presence of antibodies. Real time PCR testing for HCV RNA for all antibody positive samples to detect active infections. National Survey (DHS) 2015 (1 -59 years) 2015(1-59 Y) HCV Ab 6.3% HCV PCR 4.4% Percentage of women and men with an active hepatitis C infection by age, Egypt 2015 30 27.8 25 23.7 20 17.6 16.1 15 women 12.4 men 10 10.8 10.4 7.1 6.9 7.3 5 4.7 5.3 3.1 3.2 1.5 1.9 0 0.69 19-15 24-20 29-25 34-30 39-35 44-40 49-45 54-50 59-55 Trends in Percentage of population age 15-59 testing positive HCV Ab, Egypt 1996-2008-2015 Chart Title 1996 2008 2015 25.8 22.9 20.1 16.6 14.2 11.8 12 10 9 total Women Men Evolution of HCV treatment and SVR rates 1989 2011 2013 2014/15 95–100 100 Number Column1 Genotype 2/genotype 3 85–97 80–90 61–79 76–82 80 66–79 60 31–44 42–46 40 33–36 18–39 6–19 11–19 10–22 SVR (%) SVR 20 0 24 48 78 DAA IFN monotherapy (weeks) IFN + ribavirin PegIFN PegIFN +PegIFN ribavirin + ribavirinSMV + BOC/TVR or SOF SOF+ + comb PegIFN + RBVRBV os Davis GL, et al.
    [Show full text]